Search results for " EVA"

showing 10 items of 1941 documents

Cisplatin-based first-line treatment of elderly patients with advanced non-small-cell lung cancer: Joint analysis of MILES-3 and MILES-4 phase III tr…

2018

Purpose To test the efficacy of adding cisplatin to first-line treatment for elderly patients with advanced non–small-cell lung cancer (NSCLC) within a combined analysis of two parallel phase III trials, MILES-3 and MILES-4. Patients and Methods Patients with advanced NSCLC who were older than age 70 years with Eastern Cooperative Oncology Group performance status 0 to 1 were randomly assigned to gemcitabine or pemetrexed, without or with cisplatin. In each trial, 382 events were required to detect a hazard ratio (HR) of death of 0.75, with 80% power and two-tailed α of .05. Trials were closed prematurely because of slow accrual, but the joint database allowed us to analyze the efficacy of …

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtyPhases of clinical researchKaplan-Meier EstimatePemetrexedDeoxycytidine03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell Lungmedicineadvanced non small cell lung cancer (NSCLC) elderly patients cisplatin MILES 3 MILES 4Progression-free survivalLung cancerSurvival rateAgedAged 80 and overAntineoplastic Combined Chemotherapy ProtocolPerformance statusbusiness.industrymedicine.diseaseGemcitabineLung Neoplasm030104 developmental biologyPemetrexedTreatment OutcomeOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisQuality of LifeFemaleCisplatinbusinessmedicine.drugHuman
researchProduct

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highli…

2017

Abstract Background Preclinical models that mimic pathological and molecular features of solitary fibrous tumour (SFT) represent an important tool to select effective regimes and novel compounds to be tested in the clinic. This study was aimed at developing two preclinical models of SFT, assessing their predictive value in the clinic and selecting potential novel effective treatments. Material and methods Two dedifferentiated-SFT (D-SFT) models obtained from patients' biopsies were grown in immunodeficient mice. The antitumour activity on these models of doxorubicin, dacarbazine (DTIC), ifosfamide (monotherapy or combination), trabectedin and eribulin was tested. Twelve SFT patients were tr…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_treatmentSolitary fibrous tumourSoft Tissue NeoplasmsDioxoleMice SCIDPharmacologyAnthracyclineMetastasichemistry.chemical_compound0302 clinical medicineSolitary Fibrous TumorRetrospective StudieTetrahydroisoquinolinesAntineoplastic Combined Chemotherapy ProtocolsTetrahydroisoquinolineMeningeal NeoplasmsMeningeal NeoplasmPleural NeoplasmTrabectedinIfosfamideKidney NeoplasmSarcomaKetonesMiddle AgedMice modelKetoneKidney NeoplasmsDacarbazineSurvival RateOncologyResponse Evaluation Criteria in Solid TumorsSolitary Fibrous Tumors030220 oncology & carcinogenesisFemalemedicine.drugEribulinHumanAdultmedicine.medical_specialtyXenograft Model Antitumor AssayAnthracyclinePleural NeoplasmsDacarbazineBlotting WesternResponse Evaluation Criteria in Solid TumorDioxolesDisease-Free Survival03 medical and health sciencesInternal medicinemedicineAnimalsHumansChemotherapyFuranDoxorubicinRetroperitoneal NeoplasmsEribulinIfosfamideSoft Tissue NeoplasmCerebellar NeoplasmsFuransResponse Evaluation Criteria in Solid TumorsRetrospective StudiesAgedChemotherapyAntineoplastic Combined Chemotherapy ProtocolRetroperitoneal Neoplasmbusiness.industryAnimalXenograftCerebellar NeoplasmXenograft Model Antitumor AssaysTreatment030104 developmental biologychemistryDoxorubicinbusinessTrabectedin
researchProduct

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

2016

// Francesco Passiglia 1, * , Giuseppe Bronte 1, * , Viviana Bazan 1, * , Clara Natoli 2 , Sergio Rizzo 1 , Antonio Galvano 1 , Angela Listi 1 , Giuseppe Cicero 1 , Christian Rolfo 3 , Daniele Santini 4 , Antonio Russo 1 1 Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy 2 Department of Medical, Oral and Biotechnological Sciences, University “G. D’Annunzio”, Chieti, Italy 3 Phase I- Early Clinical Trials Unit, Oncology Department and Multidisciplinary Oncology Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium 4 Medical Oncology Department, Campus Biomedico, University of Rome, Rome, Italy * These auth…

0301 basic medicineOncologyPD-L1medicine.medical_specialtyLung NeoplasmsAnti-PD1/PD-L1 MoAbsmedicine.medical_treatmentAnti-PD1/PD-L1 MoAbAntineoplastic AgentsCochrane LibraryNSCLCB7-H1 Antigen03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungPD-L1Internal medicineOutcome Assessment Health CareBiomarkers TumorOdds RatioHumansMedicineLung cancerBiologybiologybusiness.industryAntibodies MonoclonalImmunotherapyOdds ratioPrognosismedicine.diseaseAnti-PD1/PD-L1 MoAbs; Immunotherapy; NSCLC; PD-L1; Predictive biomarker; OncologyImmunohistochemistryClinical trialPredictive biomarker030104 developmental biologyClinical trials unitOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisImmunologybiology.proteinHuman medicineImmunotherapybusinessResearch Paper
researchProduct

Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer

2016

Colorectal cancer is the third most common cancer worldwide. The prognosis of colorectal cancer patients still remains dismal and half of them will develop metastatic disease. Angiogenesis plays an essential role in colorectal tumorigenesis, and the VEGF pathway is one of the targets that has been validated up to now. The use of antiangiogenics along with chemotherapy has become an accepted standard for colorectal cancer.This review discusses the efficacy and safety profile of ramucirumab, a fully human immunoglobulin G1 monoclonal antibody against the vascular endothelial growth factor receptor-2 (VEGFR-2), for the treatment of second-line metastatic colorectal cancer upon progression to f…

0301 basic medicineOncologymedicine.medical_specialtyBevacizumabAngiogenesisColorectal cancermedicine.medical_treatmentDrug Evaluation PreclinicalAngiogenesis InhibitorsDiseaseAntibodies Monoclonal HumanizedToxicologyRamucirumab03 medical and health scienceschemistry.chemical_compoundClinical Trials Phase II as Topic0302 clinical medicineInternal medicinemedicineAnimalsHumansRandomized Controlled Trials as TopicPharmacologyChemotherapyClinical Trials Phase I as TopicNeovascularization Pathologicbusiness.industryAntibodies MonoclonalCancerGeneral Medicinemedicine.diseaseVascular endothelial growth factorDisease Models Animal030104 developmental biologyClinical Trials Phase III as Topicchemistry030220 oncology & carcinogenesisColorectal Neoplasmsbusinessmedicine.drugExpert Opinion on Drug Metabolism & Toxicology
researchProduct

Lymphocytes as a Biomarker of Frailty Syndrome: A Scoping Review

2021

Frailty is a geriatric syndrome characterized by a decrease in physiological reserve and reduced resistance to stress, as a result of an accumulation of multiple deficits in physiological systems. Frailty increases the vulnerability to adverse events and is associated with the aging process. Several studies show an association between frailty syndrome and altered blood lymphocyte levels, which is therefore potentially useful for monitoring interventions to improve or delay frailty. The main objective of this review is to provide an analysis of the current evidence related to changes in lymphocyte counts and their associations with frailty syndrome. To that end, the literature published in t…

0301 basic medicineOncologymedicine.medical_specialtyLymphocyteFrailty syndromeReview03 medical and health sciences0302 clinical medicineInternal medicineCD4 cellsMedicineAdverse effectgeriatric evaluationbusiness.industryCD8-cellsRbiomarkersmedicine.diseaseimmunityBlood lymphocyte030104 developmental biologymedicine.anatomical_structuregender differences030220 oncology & carcinogenesisBiomarker (medicine)MedicinebusinessDiseases
researchProduct

Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence…

2021

The introduction of checkpoint inhibitors (ICIs) in renal cell carcinoma (RCC) treatment landscape, resulted in improvements in overall survival (OS) in metastatic patients. Brain metastases (BMs) are a specific metastatic site of interest representing a predictive factor of poor prognosis. Patients with BMs were usually excluded from prospective clinical trials in the past. Despite recent evidence suggest the efficacy and safety of ICIs, the BMs treatment remains a challenge; the immunotherapy responsiveness seems to be multifactorial and dependent on several factors, such as the genetic intratumor heterogeneity and the immunosuppressive role of the brain tumor microenvironment. This revie…

0301 basic medicineOncologymedicine.medical_specialtySettore MED/06 - Oncologia MedicaImmune checkpoint inhibitorsmedicine.medical_treatmentImmune-checkpoint inhibitorsBrain tumorEpigenetic remodeling03 medical and health sciences0302 clinical medicineImmune systemRenal cell carcinomaInternal medicineTumor MicroenvironmentHumansMedicineProspective StudiesEpigeneticsCarcinoma Renal CellImmune Checkpoint InhibitorsBrain Neoplasmsbusiness.industrySettore MED/37 - NeuroradiologiaCancerBrain metastasesHematologyImmunotherapymedicine.diseaseKidney NeoplasmsRenal cell carcinomaClinical trialRenal cancer030104 developmental biologyOncology030220 oncology & carcinogenesisImmunotherapySettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessBrain tumor microenvironmentNeuroradiological response evaluationCritical Reviews in Oncology/Hematology
researchProduct

Identification of potential therapeutic compounds for Parkinson's disease using Drosophila and human cell models.

2017

Abstract Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. It is caused by a loss of dopaminergic neurons in the substantia nigra pars compacta, leading to a decrease in dopamine levels in the striatum and thus producing movement impairment. Major physiological causes of neurodegeneration in PD are oxidative stress (OS) and mitochondrial dysfunction; these pathophysiological changes can be caused by both genetic and environmental factors. Although most PD cases are sporadic, it has been shown that 5–10% of them are familial forms caused by mutations in certain genes. One of these genes is the DJ-1 oncogene, which is involved in an early…

0301 basic medicineParkinson's diseaseProtein Deglycase DJ-1Drug Evaluation PreclinicalSubstantia nigraNerve Tissue ProteinsBiologymedicine.disease_causeBiochemistryAnimals Genetically Modified03 medical and health sciences0302 clinical medicineDopaminePhysiology (medical)Cell Line TumorDrug DiscoverymedicineAnimalsDrosophila ProteinsHumansGeneticsMutationPars compactaNeurodegenerationDopaminergicParkinson Diseasemedicine.diseaseDisease Models AnimalOxidative Stress030104 developmental biologyGene Knockdown TechniquesMutationCancer researchDrosophila030217 neurology & neurosurgeryOxidative stressLocomotionmedicine.drugFree radical biologymedicine
researchProduct

On the presence and immunoregulatory functions of extracellular microRNAs in the trematode Fasciola hepatica.

2017

Summary Liver flukes represent a paraphyletic group of endoparasitic flatworms that significantly affect man either indirectly due to economic damage on livestock or directly as pathogens. A range of studies have focussed on how these macroscopic organisms can evade the immune-system and live inside a hostile environment such as the mammalian liver and bile-ducts. Recently, microRNAs, a class of short non-coding gene-regulators, have been proposed as likely candidates to play roles in this scenario. MicroRNAs (miRNAs) are key players in development and pathogenicity and are highly conserved between metazoans: identical miRNAs can be found in flatworms and mammalians. Interestingly, miRNAs a…

0301 basic medicinePathologymedicine.medical_specialtyFascioliasis030231 tropical medicineImmunologyGenomeHost-Parasite Interactions03 medical and health sciences0302 clinical medicineHepaticamicroRNAmedicineFasciola hepaticaAnimalsHumansDicrocoeliumImmune EvasionGeneticsbiologyHost (biology)Dicrocoelium dendriticumRNALiver flukeDicrocoeliasisFasciola hepaticabiology.organism_classificationMicroRNAs030104 developmental biologyLiverImmunologyParasitologyParasite immunology
researchProduct

The role of spatial structure in the evolution of viral innate immunity evasion: A diffusion-reaction cellular automaton model

2020

Most viruses have evolved strategies for preventing interferon (IFN) secretion and evading innate immunity. Recent work has shown that viral shutdown of IFN secretion can be viewed as a social trait, since the ability of a given virus to evade IFN-mediated immunity depends on the phenotype of neighbor viruses. Following this idea, we investigate the role of spatial structure in the evolution of innate immunity evasion. For this, we model IFN signaling and viral spread using a spatially explicit approximation that combines a diffusion-reaction model and cellular automaton. Our results indicate that the benefits of preventing IFN secretion for a virus are strongly determined by spatial struct…

0301 basic medicinePhysiologyApoptosisVirus ReplicationBiochemistryVirionsEpitopes0302 clinical medicineInterferonMedicine and Health SciencesBiology (General)Innate Immune Systemeducation.field_of_studyCell DeathEcology3. Good healthCell biologyPhenotypeComputational Theory and MathematicsCell ProcessesModeling and SimulationViral evolutionHost-Pathogen InteractionsVirusesSignal TransductionResearch Articlemedicine.drugEvolutionary ImmunologyQH301-705.5ImmunologyPopulationViral StructureBiologyAntiviral AgentsMicrobiologyViral EvolutionVirusViral Proteins03 medical and health sciencesCellular and Molecular NeuroscienceImmunityVirologyGeneticsmedicineAnimalsHumansComputer SimulationSocial BehavioreducationMolecular BiologySecretionEcology Evolution Behavior and SystematicsImmune EvasionEvolutionary BiologyInnate immune systemVirionBiology and Life SciencesProteinsCell BiologyEvasion (ethics)Immunity InnateOrganismal Evolution030104 developmental biologyViral replicationImmune SystemMicrobial EvolutionInterferonsPhysiological Processes030217 neurology & neurosurgery
researchProduct

Prospective Evaluation of Free Energy Calculations for the Prioritization of Cathepsin L Inhibitors.

2017

Improving the binding affinity of a chemical series by systematically probing one of its exit vectors is a medicinal chemistry activity that can benefit from molecular modeling input. Herein, we compare the effectiveness of four approaches in prioritizing building blocks with better potency: selection by a medicinal chemist, manual modeling, docking followed by manual filtering, and free energy calculations (FEP). Our study focused on identifying novel substituents for the apolar S2 pocket of cathepsin L and was conducted entirely in a prospective manner with synthesis and activity determination of 36 novel compounds. We found that FEP selected compounds with improved affinity for 8 out of …

0301 basic medicinePrioritizationMolecular modelHalogenationStereochemistryCathepsin LComputational biology01 natural sciencesMolecular Docking SimulationProspective evaluationCathepsin L03 medical and health sciences0103 physical sciencesDrug DiscoveryHumansEnzyme InhibitorsBinding Sites010304 chemical physicsbiologyChemistryMolecular Docking Simulation030104 developmental biologyPyrimidinesDocking (molecular)Drug Designbiology.proteinMolecular MedicineThermodynamicsProtein BindingJournal of medicinal chemistry
researchProduct